זאפה 7.5 Izraelis - hebrajų - Ministry of Health

זאפה 7.5

unipharm ltd, israel - olanzapine - טבליות מצופות פילם - olanzapine 7.5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zappa is indicated for the management of the manifestations of psychotic disorders. zappa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment zappa is indicated for the prevention of reccurence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

זאפה 10 Izraelis - hebrajų - Ministry of Health

זאפה 10

unipharm ltd, israel - olanzapine - טבליות מצופות פילם - olanzapine 10 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zappa is indicated for the management of the manifestations of psychotic disorders. zappa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment zappa is indicated for the prevention of reccurence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

אולנזאפין דקסל 5 מ"ג Izraelis - hebrajų - Ministry of Health

אולנזאפין דקסל 5 מ"ג

dexcel pharma technologies ltd - olanzapine 5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

אולנזאפין דקסל 7.5 מ"ג Izraelis - hebrajų - Ministry of Health

אולנזאפין דקסל 7.5 מ"ג

dexcel pharma technologies ltd - olanzapine 7.5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

אולנזאפין דקסל 10 מ"ג Izraelis - hebrajų - Ministry of Health

אולנזאפין דקסל 10 מ"ג

dexcel pharma technologies ltd - olanzapine 10 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder : the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

אולנזאפין דקסל 15 מ"ג Izraelis - hebrajų - Ministry of Health

אולנזאפין דקסל 15 מ"ג

dexcel pharma technologies ltd - olanzapine 15 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

אולנזאפין דקסל 20 מ"ג Izraelis - hebrajų - Ministry of Health

אולנזאפין דקסל 20 מ"ג

dexcel pharma technologies ltd - olanzapine 20 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

זאפה ODT 5 Izraelis - hebrajų - Ministry of Health

זאפה odt 5

unipharm ltd, israel - olanzapine - טבליות מסיסות בפה - olanzapine 5 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zappa odt is indicated for the management of the manifestations of psychotic disorders. zappa odt is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zappa odt is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa odt with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

זאפה ODT 10 Izraelis - hebrajų - Ministry of Health

זאפה odt 10

unipharm ltd, israel - olanzapine - טבליות מסיסות בפה - olanzapine 10 mg - olanzapine - olanzapine - acute and maintenance treatment of schizophrenia. zappa odt is indicated for the management of the manifestations of psychotic disorders. zappa odt is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment zappa odt is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa odt with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

סאפריס 5 מג Izraelis - hebrajų - Ministry of Health

סאפריס 5 מג

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - טבליות למתן מתחת ללשון - asenapine as maleate 5 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.